HUE066238T2 - Kladribin alkalmazása autoimmun neuromuszkuláris betegség kezelésére - Google Patents

Kladribin alkalmazása autoimmun neuromuszkuláris betegség kezelésére

Info

Publication number
HUE066238T2
HUE066238T2 HUE18739593A HUE18739593A HUE066238T2 HU E066238 T2 HUE066238 T2 HU E066238T2 HU E18739593 A HUE18739593 A HU E18739593A HU E18739593 A HUE18739593 A HU E18739593A HU E066238 T2 HUE066238 T2 HU E066238T2
Authority
HU
Hungary
Prior art keywords
cladribine
treatment
neuromuscular disease
autoimmune neuromuscular
autoimmune
Prior art date
Application number
HUE18739593A
Other languages
English (en)
Hungarian (hu)
Inventor
Konrad Rejdak
Original Assignee
Chord Therapeutics Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chord Therapeutics Sa filed Critical Chord Therapeutics Sa
Publication of HUE066238T2 publication Critical patent/HUE066238T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
HUE18739593A 2017-07-21 2018-06-28 Kladribin alkalmazása autoimmun neuromuszkuláris betegség kezelésére HUE066238T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1711800.1A GB2564717A (en) 2017-07-21 2017-07-21 Use of cladribine for treating autoimmune neuromuscular disease

Publications (1)

Publication Number Publication Date
HUE066238T2 true HUE066238T2 (hu) 2024-07-28

Family

ID=59771723

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE18739593A HUE066238T2 (hu) 2017-07-21 2018-06-28 Kladribin alkalmazása autoimmun neuromuszkuláris betegség kezelésére

Country Status (16)

Country Link
US (2) US12171775B2 (OSRAM)
EP (2) EP3654989B1 (OSRAM)
JP (1) JP7186214B2 (OSRAM)
CA (1) CA3095893A1 (OSRAM)
DK (1) DK3654989T3 (OSRAM)
ES (1) ES2974423T3 (OSRAM)
FI (1) FI3654989T3 (OSRAM)
GB (1) GB2564717A (OSRAM)
HR (1) HRP20240282T1 (OSRAM)
HU (1) HUE066238T2 (OSRAM)
LT (1) LT3654989T (OSRAM)
PL (1) PL3654989T3 (OSRAM)
PT (1) PT3654989T (OSRAM)
RS (1) RS65246B1 (OSRAM)
SI (1) SI3654989T1 (OSRAM)
WO (1) WO2019016505A1 (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2601786A (en) 2020-12-10 2022-06-15 Chord Therapeutics S A R L Use of cladribine for treating immune brain disease
WO2025125527A1 (en) 2023-12-14 2025-06-19 Ares Trading S.A. Cladribine regimen for treating myasthenia gravis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1269659A (en) 1984-08-06 1990-05-29 Brigham Young University Method for the production of 2'-deoxyadenosine compounds
US5310732A (en) 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US5208327A (en) 1991-12-18 1993-05-04 Ortho Pharmaceutical Corporation Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
WO2001007054A1 (en) * 1999-07-22 2001-02-01 Supergen, Inc. Methods for treating autoimmune diseases
US20040162263A1 (en) * 2002-10-31 2004-08-19 Supergen, Inc., A Delaware Corporation Pharmaceutical formulations targeting specific regions of the gastrointesinal tract
US20040102201A1 (en) * 2002-11-22 2004-05-27 Levin Robert E. System and method for language translation via remote devices
CA2520522C (en) 2003-03-28 2012-05-29 Ivax Corporation Cladribine formulations for improved oral and transmucosal delivery
DK2805723T3 (da) 2004-12-22 2018-01-29 Merck Serono Sa Cladribin-regime til behandling af multipel sclerose
CA2649810A1 (en) * 2006-05-24 2007-11-29 Laboratoires Serono S.A. Cladribine regimen for treating multiple sclerosis

Also Published As

Publication number Publication date
US12171775B2 (en) 2024-12-24
PT3654989T (pt) 2024-02-28
CA3095893A1 (en) 2019-01-24
PL3654989T3 (pl) 2024-05-20
EP3654989B1 (en) 2024-01-03
WO2019016505A1 (en) 2019-01-24
US20200163986A1 (en) 2020-05-28
ES2974423T3 (es) 2024-06-27
GB201711800D0 (en) 2017-09-06
EP4292663A3 (en) 2024-03-20
HRP20240282T1 (hr) 2024-05-10
EP3654989A1 (en) 2020-05-27
EP4292663A2 (en) 2023-12-20
LT3654989T (lt) 2024-03-25
JP7186214B2 (ja) 2022-12-08
JP2020527156A (ja) 2020-09-03
RS65246B1 (sr) 2024-03-29
SI3654989T1 (sl) 2024-06-28
DK3654989T3 (da) 2024-02-26
GB2564717A (en) 2019-01-23
US20250302858A1 (en) 2025-10-02
FI3654989T3 (fi) 2024-03-21

Similar Documents

Publication Publication Date Title
IL272410A (en) Cytokine conjugates for the treatment of autoimmune diseases
LT3240554T (lt) Blautia stercosis ir wexlerae, skirtos naudoti uždegiminių ir autoimuninių ligų gydymui
PL3157512T3 (pl) Zastosowanie kannabidioli w leczeniu padaczki
IL310483A (en) Major histocompatibility complex-based chimeric receptors and uses thereof for treating autoimmune diseases
PL3265053T3 (pl) Sposoby leczenia skóry
GB201411496D0 (en) Use of 7-Oh-Cannabidiol (7-Oh-CBD) and/or 7-Oh-Cannabidvarin (7-Oh-CBDV) in the treatment of epilepsy
IL259281B (en) History of bipyrazolyl used in the treatment of autoimmune diseases
HUE061761T2 (hu) Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében
HRP20180260T1 (hr) Dimer buprenorfina i njegova uporaba u liječenju gastrointestinalnih poremećaja
EP3341074A4 (en) IMPLANTABLE STIMULATION ASSEMBLY
HUE056871T2 (hu) RNS az autoimmun betegségek kezelésére
EP3448263A4 (en) Electrotherapeutic treatment
IL254142B (en) Tredifitant for use in the treatment of a disease or medical condition that responds to Tredifitent
IL250990A0 (en) Materials for human care
PL3277280T3 (pl) Izomiosmina do zastosowania w leczeniu chorób autoimmunologicznych
IL254173A0 (en) Oligonucleotides matching col7a1 exon 73 for epidermolysis bullosa therapy
GB201417163D0 (en) Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases
PL3129483T3 (pl) Terapia skojarzona do leczenia chorób autoimmunologicznych
HRP20180071T1 (hr) Upotreba kladribina u liječenju očnog neuromijelitisa
EP3458062A4 (en) Treatment of pain
PT3177599T (pt) Análogos fumarato e utilizações dos mesmos no tratamento de uma doença autoimune ou uma doença inflamatória
HUE066238T2 (hu) Kladribin alkalmazása autoimmun neuromuszkuláris betegség kezelésére
PL3675879T3 (pl) Cerebrolizyna do zastosowania w leczeniu cadasil
IL272422A (en) Methods for treating diseases of the meninges
PL3302463T3 (pl) Zastosowanie 3 deoksyantocyjanidyn w leczeniu chorób oczu